Fagron Sterile Services Enhances U.S. Injectable Medicines Supply via Project PROTECT Initiative

Strengthening the U.S. Supply of Injectable Medicines

Fagron Sterile Services (FSS) has announced a pivotal achievement in bolstering the supply of crucial injectable medicines within the U.S. healthcare system. Recently, they marked their full production readiness of Sterile Water for Injection (SWFI) through an initiative known as Project PROTECT. This advancement signifies a proactive approach to countering drug shortages and ensuring patient safety across the nation.

A Commitment to Patient Care

This initiative reflects FSS's unwavering dedication to enhancing domestic manufacturing capabilities as a shield against potential drug shortages. Project PROTECT has proven to be more than just a funding mechanism; it has become integral in fostering collaborations that prioritize patient access to essential medications. Previously, a grant from Project PROTECT in 2024 enabled the production of Dextrose 70%, a critical sterile injectable during a drastic fluid shortage affecting over a thousand patients. With this latest endeavor, FSS is set to further its impact by ensuring a steady supply of high-quality injectable drugs to healthcare providers throughout the United States.

Infrastructure Investments for the Future

Fagron Sterile Services has made strategic investments in its domestic production infrastructure through both Project PROTECT grants, enhancing not only the capabilities associated with the designated medications but also enriching their broader manufacturing potential. Ray Dixon, Senior Vice President of Fagron Sterile Services, elucidated, "By investing in long-term infrastructure and capacity, we are strengthening our foundation of sterile injectable manufacturing in the United States."

This investment strategy is designed to empower FSS to support crucial medications, including both Dextrose 70% and SWFI, enabling them to swiftly adapt to future supply challenges while maintaining a commitment to uninterrupted patient care.

Enhancing Supply Chain Resilience

FSS’s focus on building redundant and responsive production capabilities positions them to tackle national drug shortages more efficiently. Enhanced automation and innovative infrastructure are crucial elements in this strategy. These advancements are key to ensuring continuity of care, especially during periods of acute national shortage. Laura Bray, Founder and President of Angels for Change, highlighted the significance of this partnership, stating, "Fagron Sterile Services has exhibited a robust commitment to advancing patient care and reinforcing supply chain resilience through proactive funding aimed at domestic manufacturing."

The collaboration between FSS and Angels for Change encompasses a unified vision of constructing sustainable and proactive mechanisms to secure patient access to vital medications, effectively navigating past supply shortages.

About Fagron Sterile Services

Fagron Sterile Services US stands at the forefront of the pharmaceutical outsourcing sector, offering ready-to-administer sterile medications to healthcare providers nationwide. The organization is committed to refining patient safety while sustaining resilience in the supply chain across several domains, including critical care, labor and delivery, ophthalmics, and pain management. To explore an array of solutions that are ready for immediate administration, visit www.fagronsterile.com.

Understanding Project PROTECT

Project PROTECT is a national grant initiative aimed at supporting U.S.-based 503B outsourcing facilities to develop ready-to-activate manufacturing capacity for medications that are at risk of shortage. This program is vital in fortifying national preparedness and protecting patient access to crucial therapies through investment in onshore production capabilities. For more information on Project PROTECT, visit www.angelsforchange.org/project-protect.

In summary, through dedicated efforts, Fagron Sterile Services is not only enhancing its own production capabilities but also forging a future where patient access to essential medications is secure and dependable.